Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

August 7, 2026

Invitation to Presentation of Egetis’ Q2 2026 Report on August 21, 2026

Read more

June 10, 2026

Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency

Read more

Regulatory

May 29, 2026

Change in the number of shares and votes in Egetis Therapeutics

Read more

Upcoming event

August 21, 2026

Interim Report Q2 2026 webcast (2:00 pm CEST/ 8:00 am EDT)

Latest presentation

April 29, 2026

Interim report Q1 2026 (webcast)

Latest Report

April 29, 2026

Interim report Q1 2026

Calendar and upcoming reports

August 21, 2026 (7:00am CEST)

Interim Report Q2 2026

September 9-11, 2026

Cantor Global Healthcare Conference

September 14-16, 2026

Morgan Stanley 24th Annual Global Healthcare Conference

November 6, 2026 (7:00am CET)

Interim Report Q3 2026

Joshua’s Story

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]